an AGC kinase of the PKC family. An atypical PKC: its activity is not regulated by Ca2+, PS, DAG or phorbol esters. Constitutively active. Note: This description may include information from UniProtKB.
Protein type: EC 188.8.131.52; Kinase, protein; Protein kinase, Ser/Thr (non-receptor); Protein kinase, AGC; AGC group; PKC family; Iota subfamily
Molecular Function: protein serine/threonine kinase activity; protein domain specific binding; protein binding; phospholipase binding; protein kinase C activity; potassium channel regulator activity; insulin receptor substrate binding; metal ion binding; protein kinase binding; ATP binding; protein kinase activity
Biological Process: protein heterooligomerization; membrane hyperpolarization; negative regulation of insulin receptor signaling pathway; signal transduction; protein amino acid phosphorylation; activation of NF-kappaB transcription factor; positive regulation of interleukin-4 production; positive regulation of glucose import; positive regulation of T-helper 2 cell differentiation; transforming growth factor beta receptor signaling pathway; negative regulation of hydrolase activity; positive regulation of cell proliferation; vesicle transport along microtubule; positive regulation of cell-matrix adhesion; inflammatory response; negative regulation of peptidyl-tyrosine phosphorylation; phospholipase D activation; platelet activation; cell migration; activation of protein kinase B; microtubule cytoskeleton organization and biogenesis; peptidyl-serine phosphorylation; long-term memory; establishment of cell polarity; actin cytoskeleton reorganization; insulin receptor signaling pathway; positive regulation of insulin receptor signaling pathway; blood coagulation; vascular endothelial growth factor receptor signaling pathway; negative regulation of protein complex assembly; negative regulation of apoptosis
LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.